CTLA (Abatacept) Prevention (TN18)

IRB
CHLA-18-00029
CTLA-4 Ig (Abatacept) for Prevention of Abnormal Glucose Tolerance (AGT) and Diabetes in Relatives At-Risk for Type 1 Diabetes Mellitus (T1DM)

Abatacept is given as an investigational study drug to relatives of someone with type 1 diabetes who have positive diabetes antibodies in an attempt to prevent or delay the onset of type 1 diabetes. See TrailNet.org website for more details.

Study Details
Clinical Trials Government Identifier
NCT01773707
Keywords
abatacept ctla-4, agt, diabetes, t1d
Eligibility
1. Be identified as having 2 or more positive autoantibodies, not including mIAA, in the TrialNet Pathway to Prevention Study (TN01). 2. Be aged 6 or older and weigh more than 16 kg. 3. Have normal glucose tolerance by oral glucose tolerance test within 7 weeks of the baseline study visit.
Does this study also recruit healthy volunteers?
No
Enrollment Status
Closed
Coordinator Contact
Debra Miller
Contact Email

dmiller@chla.usc.edu